Abacavir/Lamivudine plus Rilpivirine Is an Effective and Safe Strategy for HIV-1 Suppressed Patients: 48 Week Results of the SIMRIKI Retrospective Study

Abacavir/Lamivudine plus Rilpivirine Is an Effective and Safe Strategy for HIV-1 Suppressed Patients: 48 Week Results of the SIMRIKI Retrospective Study

Objectives: Based on data from clinical practice, we evaluated the effectiveness and safety of switching to abacavir/lamivudine plus rilpivirine (ABC/3TC+RPV) treatment in virologically suppressed HIV-1-infected patients. Methods: We performed a multicenter, non-controlled, retrospective study of HI...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Troya, Jesús, Ryan, Pablo, Ribera, Esteban, Podzamczer Palter, Daniel, Hontanon, Victor, Terrón, Jose Alberto, Boix, Vicente, Moreno, Santiago, Barrufet, Pilar, Castaño, Manuel, Carrero, Ana, Galindo, María José, Suárez Lozano, Ignacio, Knobel, Hernando, Raffo, Miguel, Solís, Javier, Yllescas, María, Esteban, Herminia, González Garcia, Juan, Berenguer, Juan, Imaz, Arkaitz, GESIDA-8314 Study Group
Format: Artikel
Sprache:eng
Schlagworte:
Antiretroviral agents
Antiretrovirals
HIV (Viruses)
Limfòcits
Lymphocytes
VIH (Virus)
Online-Zugang:Volltext bestellen
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Objectives: Based on data from clinical practice, we evaluated the effectiveness and safety of switching to abacavir/lamivudine plus rilpivirine (ABC/3TC+RPV) treatment in virologically suppressed HIV-1-infected patients. Methods: We performed a multicenter, non-controlled, retrospective study of HIV-1-infected patients who switched treatment to ABC/3TC+RPV. Patients had an HIV-RNA